
USANA Executive Chairman Kevin Guest Invites All to Discover Freedom in July
Research reveals countless global celebrations honoring freedom—from America's Independence Day on July 4 to the unifying spirit of Canada Day on July 1 and numerous others around the world.
"Freedom is more than a national observance; it's deeply personal, complex and transformational," said Guest, author of All the Right Reasons: 12 Timeless Principles for Living a Life in Harmony. "Even if freedom may feel out of reach, I invite everyone to take control of their own personal independence and live a life in harmony."
To honor freedom in one's life, Guest lists five ways to break free and celebrate the possibilities.
Release Limiting Beliefs:"Are you stuck in rigid narratives about what you can or cannot do? Rewrite them," he said. "Freedom flourishes when your belief system aligns with your true potential."
Overcome Self-Doubt:"I've learned there is power in silencing the inner critic," Guest said. "To do so, recognize your achievements, no matter how small, and lean into your strengths. Confidence isn't a luxury; it's a necessity."
Leave Toxic Relationships Behind:"Whether it's a friendship, partnership or professional connection, anything that drains your energy and stifles your growth needs to be booted. You deserve better," said Guest, who speaks to tens of thousands of associates around the world each year.
Defeat Loneliness: Build bridges, not walls. "Surround yourself with people who celebrate your wins and uplift you when life gets you down. A strong network of supporters brings a solid sense of freedom," he said.
Say Goodbye to Burnout and People-Pleasing:"Stop setting yourself on fire to keep others warm," said Guest. "It's vital to set boundaries, rest, and celebrate the freedom to prioritize yourself."
In one example of negative self-talk, Guest was preparing to perform with Collin Raye's band at the Grand Ole Opry for the first time when his negative self-talk nearly immobilized him.
"Standing backstage waiting for our turn to go on, I became increasingly anxious as I convinced myself these negative thoughts were true," Guest wrote in his bestseller. "My hands started shaking, and my mouth went dry. How was I supposed to play and sing? I couldn't remember the notes to the first song, let alone the others that followed. My stomach hurt and my confidence plummeted. All I could think was, 'You're going to screw this up!'"
To his relief, he had a successful Grand Ole Opry performance and concluded, "Most of what we worry about never happens or is beyond our control."
Simply put, worry hampers creativity, induces anxiety and destroys peace.
"I have consistently found my grandfather's words to be true: if you are prepared, good things will happen," Guest said.
These five actions above not only reflect personal empowerment but also embody the harmony Guest speaks of in his book. Freedom isn't granted; it's created. It's not something to wait for; it's something to own.
"Global celebrations of freedom may vary, but the essence is the same," he said. "Freedom inspires joy, cultivates confidence and transforms lives. Begin today and champion your own independence."
More inspiring examples of amplifying self-care are shared throughout All the Right Reasons, where all proceeds go to feeding hungry children. Each book purchase provides 40 meals. For more information, visit www.kevinguest.com.
USANA Health Sciences, a global leader in health and wellness products, has long recognized the importance of social wellness in building a successful business. From its founding in 1992, USANA has focused on clear and concise communication to build trust with its customers and distributors in 25 countries. For more information about USANA Health Sciences and its dedication to promoting health, wellness, and entrepreneurial success, visit USANA.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
44 minutes ago
- CTV News
Newmarket honours late advocate Kevin Mills with highest town award
The Town of Newmarket awards its highest honour posthumously to former advanced care paramedic Kevin Mills. The Town of Newmarket paid tribute to the legacy of Kevin Mills, a tireless accessibility advocate and former advanced care paramedic, who passed away in April. On Wednesday, the Town recognized Mills posthumously at Fairy Lake Park with the Honorary Citizen Award, which is awarded to those who make a significant impact in the community and inspire future generations. Mills was a champion of inclusivity and accessibility in Newmarket. After sustaining a catastrophic spinal cord injury in 2009, the Town says he refused to let his disability define him. Instead, he and his wife Heather founded the Walk it Off spinal recovery centre and created the non-profit Peddling Possibilities to support and inspire people with disabilities to become more active. Kevin Mills honoured in Newmarket The Honorary Citizen monument at Fairy Lake Park in Newmarket, Ont. (Town of Newmarket) In 2023, the Town says Mills hand-cycled across Canada to raise awareness and support for people with disabilities, earning him Newmarket's Key to the City. 'Kevin's strength, determination and commitment to making our community more inclusive is an inspiration to us all. His courage in overcoming adversity and his passion for advocating on behalf of those with disabilities truly makes him a remarkable role model and hero,' stated Mayor John Taylor. Mills' family unveiled a permanent plaque and accepted the Honorary Citizen Award on his behalf.


Globe and Mail
an hour ago
- Globe and Mail
MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations
Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention ('CDC') adopted new recommendations for the use of RSV vaccines in the upcoming respiratory virus season. The revised recommendations lower the recommended age for RSV vaccination. Now, adults aged 50-59 who are at higher risk of severe illness from the disease are advised to receive a single dose of the vaccine. The previous CDC guidance recommended RSV vaccines for people aged 75 and older, as well as those aged between 60-74 who were at high risk of the disease. Per the CDC's website, this recommendation was officially adopted last week by the current HHS secretary, Robert F. Kennedy, Jr. Although the CDC director typically accepts or rejects such recommendations, the position is currently vacant, so Kennedy fulfilled that role. President Trump has backed Susan Monarez as his nominee for the post, but her appointment is still pending confirmation by the U.S. Senate. The broader recommendations come as a surprise because the members of the CDC's advisory committee — who initially made the recommendation earlier this year — were all removed by RFK Jr. last month. MRNA Stock Price Performance Year to date, the stock has lost 27% compared with the industry 's 2% decline. How Does the Revised CDC Guidance Benefit Moderna? The expanded CDC recommendations widen Moderna's addressable market for its RSV vaccine, mResvia. By lowering the recommended age group, the guidance opens up a new segment of eligible patients who were previously excluded. Moderna is one of a handful of companies marketing an RSV vaccine. Though mResvia was initially approved last year for use in people aged 60 and older, the FDA expanded its label last month to include high-risk individuals aged between 18-59. Despite commercially launching the vaccine last year, mResvia sales were modest as it was approved and recommended later in the contracting season. By that point, many people had already completed their vaccinations with either GSK 's GSK Arexvy or Pfizer 's PFE Abrysvo. RSV vaccines gained traction in 2023 with the initial approvals of Arexvy and Abrysvo — the first FDA-approved RSV vaccines. At the time, the CDC issued blanket approvals for use among individuals aged 60 and older. However, the CDC later narrowed that guidance, which trimmed the target market last year. That, combined with the earlier availability of GSK and Pfizer's offerings, gave both companies a dominant position over Moderna. Both GSK and Pfizer vaccines are already approved for use in individuals aged 60 and older. While GSK's Arexvy is approved for use in high-risk individuals aged 50-59, PFE's Abrysvo is approved for use in high-risk people aged 18-59. The Pfizer vaccine is also approved for use in infants through maternal immunization. MRNA's Zacks Rank Moderna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Moderna, Inc. (MRNA): Free Stock Analysis Report This article originally published on Zacks Investment Research (


Globe and Mail
an hour ago
- Globe and Mail
Will The Decline in Legacy Drugs Pull Down BMY's Top Line?
BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Revenues for the Legacy Portfolio plunged 20% in the first quarter to $5.64 billion due to the continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane, as well as the effects of the U.S. Medicare Part D redesign. Blood thinner drug Eliquis' sales of $3.56 billion were down 4% due to the impact of Medicare Part D redesign in the United States. The company expects sales to steadily increase in the second half of 2025 due to the elimination of the coverage gap. Multiple myeloma (MM) drug Revlimid revenues plummeted 44% to $936 million due to lower demand on account of generic erosion. MM drug Pomalyst generated sales of $658 million, down 24% year over year. Leukemia drug Sprycel sales nosedived 53% year over year to $175 million due to generic competition. Abraxane revenues declined 52% to $105 million. While drugs like Reblozyl, Breyanzi, Camzyos and Opdualag have enabled BMY to stabilize its revenue base, an important point to consider is that the legacy portfolio sales accounted for 50% of total sales in the first quarter. Competition for BMY's Key Drugs BMY's growth portfolio primarily comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others. Oncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space. However, BMY faces competition from large pharma companies like Merck MRK and Pfizer PFE. The immuno-oncology space is dominated by Merck's blockbuster drug Keytruda (pembrolizumab). Keytruda is approved for several types of cancer and alone accounts for around 50% of its MRK's pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda. Pfizer has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies that treat a wide range of cancers, including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer. Pfizer also has oncology biosimilars in its portfolio and markets six of them for cancer. BMY's Price Performance, Valuation and Estimates Shares of Bristol Myers have lost 14% year to date compared with the industry 's decline of 0.6%. From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, BMY's shares currently trade at 7.45x forward earnings, lower than its mean of 8.86x and the large-cap pharma industry's 15.09X. The Zacks Consensus Estimate for 2025 earnings per share has moved down to $6.76 from $6.89 in the past 60 days and that for 2026 is down five cents. BMY currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report This article originally published on Zacks Investment Research (